Join
Live feed
·
PRReleasevia Quantisnow
Pharvaris N.V. logo

Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet

ByQuantisnow·Wall Street's wire, on your screen.
PHVS· Pharvaris N.V.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PHVS (Pharvaris N.V.) and more on Quantisnow.